BCS

Barclays lowered its price target on PepsiCo to $144 from $158 and kept its Equal Weight rating. The firm cited concerns that the North American foods turnaround is losing momentum. Last week, JPMorgan cut its price target on PepsiCo to $170 from $178, citing weaker pricing, product mix and soft demand trends. PepsiCo (PEP) stock is facing caution from Wall Street after Barclays lowered its price target on the beverage and snacks giant ahead of its second-quarter earnings, reflecting growing concerns about the pace of recovery in the company’s North American food business. Barclays cut its price target on PepsiCo shares to $144 from $158 while maintaining an ‘Equal Weight’ rating, citing concerns that improvements seen earlier this year may be difficult to maintain. See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox Analysts at Barclays said PepsiCo has lagged behind many of its consumer staples peers as investors question whether the company's turnaround strategy for its North American foods segment can deliver lasting results. According to the firm, ongoing weakness in the company's core unflavored snack portfolio continues to limit the potential for a stronger recovery. In addition to trimming its price target, Barclays reduced its sales projections for PepsiCo ahead of the Q2 earnings. The firm believes the company's operational improvements have not advanced enough to fully offset continued challenges in key product categories. PepsiCo stock edged 0.08% lower overnight, ahead of Monday. UBS also lowered its price target on PepsiCo to $172 from $186. Last week, JPMorgan reduced its price target on PepsiCo to $170 from $178 but maintained an ‘Overweight’ rating, reflecting continued confidence in the company's longer-term outlook despite softer near-term expectations. The firm lowered its Q2 forecasts, expecting weaker pricing, a less favorable product mix and slower revenue growth than previously expected. JPMorgan also said recent sales data points to soft demand, leading to a more cautious outlook for the quarter. According to Koyfin data, analysts expect PepsiCo to report Q2 revenue of $23.9 billion and earnings of $2.21 per share. PepsiCo has been relying heavily on price increases to offset inflation over the past two years. So the Q2 results are expected to offer insight...

Barclays flagged that the sentiment surrounding the stock and its valuation is "at all-time lows." The company’s CEO, Kristin Peck, told analysts during the Q1 earnings call in May that competition intensified across key pet care categories. Zoetis cut its 2026 revenue outlook to the $9.68 billion to $9.96 billion range, and adjusted EPS in the $6.85 to $7.00 range. Shares of Zoetis (ZTS) attracted investor attention on Wednesday after Barclays issued fresh commentary on the animal health pharmaceutical company, saying that competitive headwinds in its companion animal portfolio may persist longer than investors expect. At the time of writing, ZTS shares were marginally down in premarket trading. See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox The firm’s commentary comes in the aftermath of Zoetis’ first-quarter earnings, which it described as “challenging.” According to TheFly, Barclays believes stabilization across the company’s key companion products "could be several quarters away." They also flagged that the sentiment surrounding the stock and its valuation is "at all-time lows." The firm maintained its neutral rating of ‘Equal Weight’ but significantly lowered the price target to $85 from $136, now implying an upside potential of only 18% as of the stock’s last closing price on Tuesday. However, data from Koyfin shows that Wall Street is largely bullish on ZTS, with 11 of 20 analysts covering the stock rating it a ‘Buy’ or higher, while the remaining rate it ‘Hold.’ The company’s CEO, Kristin Peck, told analysts during the first-quarter (Q1) earnings call in May that competition intensified across key pet care categories, including dermatology and parasiticides, with additional pressure in vaccines from certain generics. "This quarter reflects pressure in parts of our companion animal portfolio where market growth has slowed, and competition has intensified," Peck had then said. A lowered full-year forecast accompanied that commentary. Zoetis cut its revenue outlook to the $9.68 billion to $9.96 billion range, from the $9.83 billion to $10.03 billion range previously expected. Adjusted earnings per share (EPS) were guided in the $6.85 to $7.00 range, from $7.00 to $7.10. The midpoints of both forecasts were below the consensus estimate. Moreover, Q1 revenue and EPS were a...

Barclays (BCS) has acquired a long-term leasehold interest in its global headquarters at One Churchi

US large-cap banks are expected to report strong second-quarter earnings and issue upbeat guidance,

NEW YORK, June 25, 2026--(BUSINESS WIRE)--Barclays PLC notes the Federal Reserve Board’s (FRB) publication of the results from its annual bank stress tests on 24 June 2026. The projected capital ratios for Barclays US LLC (Barclays’ US intermediate holding company) remained above the regulatory minimum required levels across all nine quarters of the test. In addition, Barclays US LLC has published its own assessment of its results under the FRB’s hypothetical supervisory severely adverse scenario, which can be found on the Barclays website at: https://home.barclays/investor-relations/investor-news/fed-filings/ About BarclaysOur vision is to be the UK-centered leader in global finance. We are a diversified bank with comprehensive UK consumer, corporate and wealth and private banking franchises, a leading investment bank and a strong, specialist US consumer bank. Through these five divisions, we are working together for a better financial future for our customers, clients and communities. For further information about Barclays, please visit our website home.barclays View source version on businesswire.com: https://www.businesswire.com/news/home/20260624637257/en/ Contacts Press Contact:Oksana Poltavets+1 (212) [email protected] Investor Relations Contact:Marina Shchukina+44 207 116 [email protected]

Royal Bank of Canada (NYSE:RY) is one of the top 10 undervalued blue chip stocks analysts recommend for smart investing. Barclays lifted the price target on Royal Bank of Canada (NYSE:RY) to C$260 from C$245 on May 29, maintaining an Overweight rating on the shares. The rating update came after the bank reported financial results for fiscal Q1 2026 on May 28, with the firm telling investors in a research note that Royal Bank of Canada’s (NYSE:RY) adjusted earnings beat expectations on better-than-anticipated fee income. In its financial results for the quarter ended April 30, 2026, the company reported net income of $5.5 billion, up $1,119 million or 25% from the previous year. Diluted EPS rose 27% over the same period to $3.85, highlighting growth across each of Royal Bank of Canada’s (NYSE:RY) business segments. Adjusted net income and adjusted diluted EPS for the quarter were $5.6 billion and $3.90, up 23% and 25%, respectively, from the prior year. Royal Bank of Canada (NYSE:RY) provides banking and financial services. The company’s operations are divided into the following segments: Personal and Commercial Banking, Wealth Management, Insurance, Capital Markets, and Corporate Support. While we acknowledge the potential of RY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow. Disclosure: None. Follow Insider Monkey on Google News.

It has been about a month since the last earnings report for Deutsche Bank (DB). Shares have added about 6.6% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Deutsche Bank due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for Deutsche Bank Aktiengesellschaft before we dive into how investors and analysts have reacted as of late. Deutsche Bank reported first-quarter 2026 earnings attributable to its shareholders of €1.91 billion ($3.26 billion), up 7.7% year over year. This Germany-based lender reported a record profit before tax of €3 billion ($5.2 billion), up 7.2% from the year-ago quarter. Increased revenues and lower expenses aided results. However, higher provisions for credit losses were a headwind. Revenues & Expenses The bank generated net revenues of €8.7 billion ($14.8 billion), up 1.7% year over year. Non-interest expenses of €5.1 billion ($8.7 billion) decreased 2% from the prior-year quarter. Provision for credit losses was €519 million ($885.4 million), up 10.2% from the prior-year quarter. Segmental Performance Corporate Bank: Net revenues from the segment were €1.8 billion ($3.1 billion), down 2.7% year over year. The results were hurt by a decrease in Institutional Client Services revenues. Investment Bank: This segment’s net revenues totaled €3.4 billion ($5.7 billion), which increased marginally year over year. The upside was primarily driven by the improvement in Investment Banking & Capital Markets revenues. Private Bank: Net revenues of €2.6 billion ($4.4 billion) rose 5.2% year over year. Asset Management: Net revenues of €802 million ($1,368.2 million) rose 9.9% year over year. An increase in management fees and performance and transaction fees led to the rise. Corporate & Other: The segment reported net revenues of €114 million ($194.5 million), down 10.2% from the prior-year quarter. Capital Position DB’s Common Equity Tier 1 capital ratio was 13.8% as of March 31, 2026, unchanged from the year-ago quarter. The leverage ratio on a fully loaded basis was 4.4%, down from the year-ago quarter's 4.6%. 2026 Deutsche Bank expects full-year revenues of around €33 billion. This is supported by banking book net interest income incr...

Marvell Technology has gained more than 200% in the past 12 months. It just reported record revenue, guided above expectations, and told investors that growth would accelerate every single quarter through the rest of the fiscal year. For Barclays analyst Tom O'Malley, that was enough to nearly double his price target in a single note. O'Malley raised his price target on Marvell Technology (MRVL) to $275 from $150 and maintained his overweight rating following the company's Q1 FY2027 earnings release on May 27, according to TipRanks. That is an 83% increase in a single note, and the rationale is specific. Barclays cited Marvell's upward revision to its outlook for fiscal 2027 and 2028 as the primary driver. The company expects its data center business to grow 50% in FY2027 and 55% in FY2028. More Wall Street: JPMorgan resets S&P 500 price target for the rest of 2026 Vanguard challenges the S&P 500 as a one-stop strategy Goldman Sachs resets Broadcom stock forecast Interconnect revenue is projected to rise more than 70% year over year in FY2027. Custom silicon revenue is expected to exceed $10 billion by 2028. Marvell's own management commentary made Barclays' case easier to argue. The company said revenue growth is expected "to continue accelerating each quarter" for the rest of the fiscal year. For an analyst trying to justify an 83% target increase, that is a useful data point. Q1 FY2027 revenue came in at $2.42 billion, up 9% sequentially. The data center segment led the way with 11% sequential growth, Investing.com reported. The Q2 guidance range came in modestly above Wall Street estimates. Marvell has posted 42% revenue growth over the trailing 12 months. Analysts are now forecasting 33% revenue growth for FY2027. The stock has gained 208% over the past year, TipRanks confirmed. It was trading at approximately $196.32 with a market cap of $171 billion at the time of the note. The Barclays thesis is not about Marvell as a general semiconductor company. It is specifically about what happens to Marvell's revenue when hyperscaler data center spending stays elevated and custom silicon demand accelerates alongside it. Marvell's custom ASIC business has become one of the most closely watched revenue lines in the AI infrastructure trade. Large cloud providers are increasingly commissioning custom chips for specific workloads rather than buying general-purpose a...

Agilent Technologies stock surges as Wall Street approves of the company’s second-quarter earnings and guidance update.

Sandisk was trading near $36 twelve months ago. It has since done something that most stocks never do in a lifetime. And on May 27, one of Wall Street's major banks looked at that run and decided the story was not finished. The argument it made for why is more specific than most investors are expecting. Barclays analyst Tom O'Malley upgraded SanDisk (SNDK) to Overweight from Equal-weight and raised his price target to $2,300 from $1,200 on May 27. The new target implies approximately 45% upside from the stock's close of $1,589.55. Shares jumped 7.5% on the day of the upgrade. More Wall Street: JPMorgan resets S&P 500 price target for the rest of 2026 Vanguard challenges the S&P 500 as a one-stop strategy Goldman Sachs resets Broadcom stock forecast The 52-week low for SanDisk was $36.21. The stock has gained more than 4,000% in the past twelve months, according to Investing.com. Barclays is saying the move is not over. The draft narrative around SanDisk upgrades has focused on memory pricing and supply cycles. O'Malley's argument is more specific and more structural than that. His core thesis is about SanDisk's contracting model, not just the market cycle it operates in. O'Malley said SanDisk has taken an "aggressive and structurally innovative" approach to its New Business Models, highlighted at the company's most recent earnings call. The NBMs are designed to deliver "demand certainty" for SanDisk while giving customers "supply assurance," according to TipRanks. The contracts vary in length, with the longest extending into 2031. They are structured around quarterly volume commitments that scale upward over the life of each agreement. Pricing combines fixed rates in the near term with variable pricing over the longer horizon, allowing SanDisk to capture upside if market prices rise. The financial scale of those agreements is the most important number in O'Malley's note: SanDisk has secured $42 billion in minimum contractual revenue and $11 billion in financial guarantees from these deals, TipRanks confirmed. That is not a cyclical trade. It is a contracted revenue floor that reduces the binary risk embedded in most memory stock calls. "We see Memory/Storage as the most attractive vertical below accelerators," O'Malley said, according to CNBC. That framing positions SanDisk directly behind AI accelerators in terms of secular demand strength, a significant st...

Canadian Imperial Bank of Commerce CM is slated to report second-quarter fiscal 2026 (ended April 30) results on May 28, before market open. The company’s quarterly earnings are expected to have increased on a year-over-year basis.In the last reported quarter, Canadian Imperial’s results were aided by record revenues across all of its business units. A year-over-year decline in provisions was another positive. However, higher expenses hurt the results to some extent.Canadian Imperial has an impressive earnings surprise history. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average beat being 9.3%. Canadian Imperial Bank of Commerce price-eps-surprise | Canadian Imperial Bank of Commerce Quote The Zacks Consensus Estimate for the company’s earnings for the to-be-reported quarter is pegged at $1.78 per share, which has been unchanged in the past seven days. The estimated figure suggests a rise of 23.6% from the year-ago quarter. The company’s capital markets division is expected to have gotten major support from elevated market volatility and stronger client activity in the April-end quarter. Also, an increase in underwriting fees, as well as higher advisory fees (on a rise in global deal volumes), is likely to have boosted investment banking revenues.On the lending side, Canadian commercial banking and retail banking operations benefited from decent lending demand and relatively resilient spreads in the quarter. Thus, loan growth and expansion in earning assets are expected to have provided support to Canadian Imperial’s net interest income.Despite NII growth, the company’s net interest margin (NIM) expansion is likely to have been constrained because of easing interest rates in Canada.Since the company has continuously been spending on technology modernization and employee compensation, overall costs are expected to have been elevated in the quarter. Per our quantitative model, it cannot be conclusively predicted whether Canadian Imperial will be able to beat the Zacks Consensus Estimate for earnings this time. This is because it does not have the right combination of the two key ingredients — positive Earnings ESP and a Zacks Rank #3 (Hold) or better.You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.Earnings ESP: The Earnings ESP for CM is 0.00%.Zacks Rank: T...

Stryker Corporation (NYSE:SYK) is one of the best robotic surgery stocks to buy. Barclays cut the price target on Stryker Corporation (NYSE:SYK) to $394 from $469 on May 4, maintaining an Overweight rating on the shares. The firm told investors in a research note that the company’s fiscal Q1 results were mixed and below the Street’s estimates. It also stated that a “significant back-end loaded ramp” is required to attain the company’s full-year guidance for the target cut. In a separate development, Truist cut the price target on Stryker Corporation (NYSE:SYK) to $380 from $395 on April 15, reaffirming a Hold rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 results in MedTech, with the firm stating that it anticipates fiscal Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes. It further stated in a research note that a premium valuation is justified for the stock given its view of the company’s high-quality, above-average revenue growth profile. However, it also prefers to have higher conviction in EPS upside and faster earnings growth potential. Stryker Corporation (NYSE:SYK) is a medical technology company that offers products and services that help improve patient and health outcomes. Its operations are divided into the MedSurg and Neurotechnology and the Orthopedics and Spine segments. While we acknowledge the potential of SYK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow. Disclosure: None. Follow Insider Monkey on Google News.